5.1 Graviditet - SBU

143. Orme ML, Lewis PJ, de Swiet M,
et al. May mothers given warfarin breastfeed
their infants? BMJ 1977;1:1564-5.
144. Pabinger I, Schneider B. Thrombotic
risk in hereditary antithrombin III, protein
C, or protein S deficiency. A cooperative,
retrospective study. Gesellschaft fur
Thrombose- und Hamostaseforschung
(GTH) Study Group on Natural Inhibitors.
Arterioscler Thromb Vasc Biol 1996;16:
742-8.
145. Pabinger I, Nemes L, Rintenen C,
et al. Pregnancy-associated risk for venous
thromboembolism and pregnancy outcome
in women honozygous for factor V Leiden.
Haemotol J 2000;1:37-44.
146. Pabinger I, Grafenhofer H, Kaider A,
et al. Preeclampsia and fetal loss in women
with a history of venous thromboembolism.
Arterioscler Thromb Vasc Biol 2001;21:
874-9.
147. Pauzner R, Dulitzki M, Langevitz P,
et al. Low molecular weight heparin and
warfarin in the treatment of patients with
antiphospholipid syndrome during
pregnancy. Thromb Haemost 2001;86:
1379-84.
148. Peeters LL, Hobbelen PM,
Verkeste CM, et al. Placental transfer
of Org 10172, a low-molecular weight
heparinoid, in the awake late-pregnant
guinea pig. Thromb Res 1986;44:277-83.
149. Pettila V, Kaaja R, Leinonen P, et al.
Thromboprophylaxis with low molecular
weight heparin (dalteparin) in pregnancy.
Thromb Res 1999;96:275-82.
150. Pettila V, Leinonen P, Markkola A,
et al. Postpartum bone mineral density
in women treated for thromboprophylaxis
with unfractionated heparin or LMW
heparin. Thromb Haemost 2002;87:182-6.
151. Polak JF, Wilkinson DL. Ultrasonographic
diagnosis of symptomatic deep
venous thrombosis in pregnancy. Am J
Obstet Gynecol 1991;165:625-9.
152. Preston FE, Rosendaal FR, Walker ID,
et al. Increased fetal loss in women with
heritable thrombophilia. Lancet 1996;348:
913-6.
153. Rai R, Cohen H, Dave M, Regan L.
Randomised controlled trial of aspirin and
aspirin plus heparin in pregnant women
with recurrent miscarriage associated with
phospholipid antibodies (or antiphospholipid
antibodies). BMJ 1997;314:253-7.
154. Rai R, Shlebak A, Cohen H, et al.
Factor V Leiden and acquired activated
protein C resistance among 1000 women
with recurrent miscarriage. Hum Reprod
2001;16:961-5.
155. Rasmussen C, Wadt J, Jacobsen B.
Thromboembolic prophylaxis with low
molecular weight heparin during pregnancy.
Int J Gynaecol Obstet 1994;47:
121-5.
156. Richter C, Huch A, Huch R. Transfer
of low molecular heparin during breast
feeding. Thromb Haemost 1997;Suppl 734.
157. Ricketts CR, Cope E, J. T. Dextran
and the placental barrier. BMJ 1966;ii:
1050.
158. Ringe JD, Keller A. [Risk of osteoporosis
in long-term heparin therapy of
thromboembolic diseases in pregnancy:
attempted prevention with ossein-hydroxyapatite].
Geburtshilfe Frauenheilkd 1992;
52:426-9.
KAPITEL 5.1 • GRAVIDITET 359